A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus

OBJECTIVE: To evaluate the safety, tolerability and efficacy of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE) beyond 1 year. METHODS: This was a 24-week, open-label extension following a 52-week, double-blind, placebo-controlled trial of belimumab SC. Patients who c...

Descripción completa

Detalles Bibliográficos
Autores principales: Doria, A, Bass, D, Schwarting, A, Hammer, A, Gordon, D, Scheinberg, M, Fox, N L, Groark, J, Stohl, W, Kleoudis, C, Roth, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066857/
https://www.ncbi.nlm.nih.gov/pubmed/29807477
http://dx.doi.org/10.1177/0961203318777634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066857/
https://www.ncbi.nlm.nih.gov/pubmed/29807477
http://dx.doi.org/10.1177/0961203318777634

Ejemplares similares